

REMARKSStatus of the Claims

Claims 1, 32-34, 39-45, 50-52, 57-61, 63-65, and 67-70 are currently pending and under examination in the present application. Claims 2-31, 35-38, 46-49, 53-56, 62, and 66 have been canceled without prejudice or disclaimer of the subject matter claimed therein.

Applicants would like to thank the Examiner for indicating Claims 1, 32-34, 39-45, 50-52, 57, 58, 63, 69, and 70 as being allowable.

Amendments to the Claims

Claims 59 and 67 have been amended.

Claim 59 has been amended to recite the features of canceled claim 66.

Claim 67 has been amended to depend from claim 59.

These amendments do not introduce prohibited new matter.

Rejection Under 35 U.S.C. § 102(a)

Claims 59-61 and 65 are rejected under 35 U.S.C. 102(a) as being anticipated by Wall *et al.* (Methods in Enzymology 309: 204-219, 1999), as evidenced by Soloman *et al.* (US 2002/0019335).

Claim 59 as amended provides a pharmaceutical composition for removing amyloid deposits comprising an adjuvant and an effective amount of amyloid fibrils comprising an immunoglobulin light chain polypeptide or a whole light chain polypeptide, heterologous to the amyloid fibrils in a subject. Claims 60, 61 and 65 depend from claim 59 and include the features of claim 59. Claim 59 as amended includes the features of claim 66 which was not included under this rejection. Thus, the present rejection is not applicable to claim 59 as it stands or to its dependent claims.

Moreover, Wall *et al.* do not teach a pharmaceutical composition comprising an adjuvant and amyloid fibrils for administering to subjects to remove amyloid deposits. Therefore, the presently claimed invention is not anticipated by Wall *et al.*


Conclusion

In view of the foregoing claim amendments and accompanying remarks, Applicants respectfully request reconsideration and timely allowance of the pending claims. Should the Examiner feel that there are any issues outstanding after consideration of this response, the Examiner is invited to contact Applicants' undersigned representative to expedite prosecution.

If there are any additional fees due in connection with the filing of this response, please charge the fees to our Deposit Account No. 50-0310. If a fee is required for an extension of time under 37 C.F.R. § 1.136 not accounted for above, such an extension is requested and the fee should also be charged to our Deposit Account.

Dated: **January 4, 2008**
Morgan, Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
202-739-3000

Respectfully submitted,
Morgan, Lewis & Bockius LLP


Sally P. Teng
Registration No. 45,397